Health Condition 1: E889- Metabolic disorder, unspecified
Conditions
Interventions
Intervention1: Not Applicable: Not Applicable
Control Intervention1: Not Applicable: Not Applicable
Sponsors
Aster CMI Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1 Adults greater than or equal to 18 years diagnosed with biopsy proven advanced or unresectable HCC. 2 Patients with BCLC stage C or BCLC stage B 3 Treatment na ve for systemic therapy. 4 Child Pugh A or B, ECOG lesser than or equal to 2 5 Signed informed consent.
Exclusion criteria
Exclusion criteria: 1 Prior liver transplant. 2 Previous systemic therapy for HCC. 3 Significant comorbidities or active infections 4 High risk esophageal or gastric varices
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess genomic alterations in biopsy-proven hepatocellular carcinoma (HCC) patients at baseline and after 3 doses of immunotherapy with Atezolizumab and Bevacizumab. Timepoint: Baseline and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the relationship between key genomic alterations e.g., CTNNB1, TERT, TP53 & immune phenotypes hot vs. cold following immunotherapy. To explore the association between genomic changes & clinical response, including tumour mutation burden TMB & immune cell infiltration. Timepoint: Baseline & 12 weeks | — |
Countries
India
Contacts
Public ContactAkhil Deshmukh
Aster Whitefield Hospital
Outcome results
None listed